Login to Your Account



Nuvelo Surges On Alfimeprase Agreement For Up To $385M

By Karen Pihl-Carey


Friday, January 6, 2006
Nuvelo Inc.'s stock benefitted Thursday when the company entered a collaboration with pharmaceutical giant Bayer HealthCare AG to develop and commercialize the cardiovascular drug alfimeprase. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription